Surgery Partners Inc

Surgery Partners Inc(SGRY)股票分析

$15.900

+0.517 (+3.25%)收盤時

Loading chart…
最高
16.000
開盤
15.520
成交量加權均價
15.75
成交量
2.91M
市值
3.09B
最低
15.345
成交金額
45.77M
企業價值/稅息折舊攤銷前利潤(TTM)
10.36

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals.

AI 分析 of Surgery Partners Inc (SGRY)

買進

Surgery Partners Inc is a good buy right now due to its current price of $14.61, which is significantly below the median analyst price target of $19, indicating a potential upside of 35.9%. Additionally, the stock has shown positive momentum with a 5-day change of +5.18% and a Relative Strength Index (RSI) of 63.79, suggesting it is gaining strength. However, investors should be cautious of the company's substantial debt of $4 billion, which poses a risk to its financial stability.

分析師評級(9)

上檔空間 +65.41%
買進
4 買進
4 持有
1 賣出
目前: 15.90
最低
18.00
平均
26.30
最高
36.00

JPMorgan

2026-09-14

目標價

$15

中性

RBC Capital

2026-08-11

目標價

$19

優於大盤

TD Cowen

2026-08-11

目標價

$19

買進

Cantor Fitzgerald

2026-08-11

目標價

$18

增持

Jefferies

2026-05-06

目標價

$17

買進

估值指標

Surgery Partners Inc(SGRY)目前預期本益比為 18.90,5 年平均預期本益比為 74.23。

預期本益比

合理
5 年均值 P/E
74.23
目前P/E
18.90
高估
212.27
低估
-63.81

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
15.70
目前EV/EBITDA
10.36
高估
19.97
低估
11.43

預期股價營收比

合理
5 年均值 P/S
1.09
目前P/S
0.72
高估
1.50
低估
0.68

Alphio AI 對 SGRY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SGRY

$22.84

情境價格

基

基準

基準 · 50%SGRY

$21.90

情境價格

悲

悲觀

悲觀 · 25%SGRY

$21.04

情境價格

持有 SGRY 的大戶

J

Jaunty Global Limited

+ 持有SGRY

+1.61%

3個月報酬率

P

Pentwater Capital Management LP

+ 持有SGRY

-8.56%

3個月報酬率

D

Davidson Kempner Capital Management LP

+ 持有SGRY

-8.58%

3個月報酬率

事件時間軸

2026-10-18 (ET)

21:00:00

Chewy Short Interest Surges to 91.3%

2026-08-23 (ET)

00:00:00

Charter Communications Short Interest Rises to 32.4%

2026-08-10 (ET)

17:00:00

Stocks Open Lower as Middle East Uncertainty Grows

12:30:00

Major Averages Mixed at Open Amid Middle East Uncertainty

08:00:00

Company Reaffirms 2026 Revenue Outlook of $3.35B to $3.45B

資訊

SGRY 常見問題 —— 由 Alphio AI 解答

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

Surgery Partners Inc is a good buy right now due to its current price of $14.61, which is significantly below the median analyst price target of $19, indicating a potential upside of 35.9%. Additionally, the stock has shown positive momentum with a 5-day change of +5.18% and a Relative Strength Index (RSI) of 63.79, suggesting it is gaining strength. However, investors should be cautious of the company's substantial debt of $4 billion, which poses a risk to its financial stability.

9 analysts cover SGRY: 4 rate it Buy, 4 Hold and 1 Sell. The average price target is 26.30.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易